Pfizer Inc., Sandwich CT13 9NJ, UK.
Polpharma SA, Starogard Gdański 83-200, Poland.
J Pharm Sci. 2018 Sep;107(9):2335-2340. doi: 10.1016/j.xphs.2018.04.009. Epub 2018 Apr 18.
To support the practical implementation of the International Council for Harmonisation (ICH) Q3D guideline, which describes a risk-based approach to the control of elemental impurities in drug products, a consortium of pharmaceutical companies has established a database to collate the results of analytical studies of the levels of elemental impurities within pharmaceutical excipients. This database currently includes the results of 26,723 elemental determinations for 201 excipients and represents the largest known, and still rapidly expanding, collection of data of this type. Analysis of the database indicates good coverage of excipients relevant to real-world drug product formulations and tested element profiles consistent with ICH Q3D recommendations. The database includes the results from multiple analytical studies for an excipient and thus incorporates within it an indication of both excipient supplier and batch-to-batch variability as well as any variability associated with the different testing organizations and methods employed. The data confirm the findings of earlier smaller studies that elemental impurity concentrations in excipients are generally low and when used in typical proportions in formulated drug products are unlikely to pose a significant patient safety risk. The database is now in active use as one line of evidence in ICH Q3D risk assessments.
为了支持国际协调理事会(ICH)Q3D 指南的实际实施,该指南描述了一种基于风险的方法来控制药物产品中的元素杂质,一个制药公司联盟已经建立了一个数据库,以整理药物辅料中元素杂质分析研究的结果。该数据库目前包含 201 种辅料的 26723 项元素测定结果,是此类数据中已知的最大且仍在快速扩展的数据集。对数据库的分析表明,它很好地涵盖了与实际药物产品配方相关的辅料,并且测试的元素概况与 ICH Q3D 建议一致。该数据库包含了辅料的多个分析研究结果,因此包含了辅料供应商和批间变异性的信息,以及与所使用的不同测试组织和方法相关的任何变异性。这些数据证实了早期较小研究的发现,即辅料中的元素杂质浓度通常较低,并且在药物产品配方中以典型比例使用时不太可能对患者安全构成重大风险。该数据库现在作为 ICH Q3D 风险评估的一条证据线在积极使用。